Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • ADC Antibody
    (40)
  • Antibody-Drug Conjugates (ADCs)
    (1)
  • EGFR
    (1)
  • IGF-1R
    (1)
  • Immunology/Inflammation related
    (1)
  • Mucin
    (1)
  • PSMA
    (1)
  • TNF
    (1)
  • TROP2
    (1)
Filter
Search Result
Results for "

adcantibody

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    42
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    42
    TargetMol | Inhibitory_Antibodies
Trastuzumab
T9912180288-69-1
Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has been clinically used to treat HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer.
  • $157
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Sacituzumab
Sacituzumab (anti-Trop-2), Sacituzumab
T353971796566-95-4
Sacituzumab is a humanized IgG1 monoclonal antibody utilized in the synthesis of antibody-active small-molecule couplings (naked antibody to Sacituzumab govitecan). It exhibits potential antitumor activity and is employed in tumor research.
  • $163
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Moxetumomab
T766931622075-65-3
Moxetumomab, a recombinant immunotoxin targeting CD22, is utilized in the study of hairy cell leukemia (HCL) [1] [2].
  • $247
In Stock
Size
QTY
Inebilizumab
VIB-0551, MT-0551, MEDI 551, 16C4-aFuc
T767131299440-37-1
Inebilizumab is a humanized anti-CD19 monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used to treat a range of autoimmune diseases associated with CD19 B cells, such as multiple sclerosis and optic neuromyelitis.
  • $157
In Stock
Size
QTY
Inotuzumab
T767901660159-36-3
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4 antibody targeting CD22. This naked antibody can be used to synthesize antibody-active molecule conjugators [Inotuzumab ozogamicin] and to study acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • $228
In Stock
Size
QTY
Lonigutamab
VB-421, VB421, hz208F2-4
T77071
Lonigutamab (hz208F2-4) is a humanized monoclonal antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) for the study of thyroid eye disease.
  • $197
In Stock
Size
QTY
Mipasetamab
T770852361055-48-1
Mipasetamab, an IgG1κ antibody, targets AXL, a tyrosine kinase receptor and TAM Receptor. It plays a crucial role in synthesizing ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC), known for its anti-tumor activity [1].
  • $332
2-4 weeks
Size
QTY
Praluzatamab
T771222145109-70-0
Praluzatamab is a monoclonal antibody targeting an activated white blood cell adhesion molecule (ALCAM CD116). It is a naked antibody used to synthesize antibody active molecule conjugates (Praluzatamab ravtansine) and can be employed to study breast cancer.
  • $228
In Stock
Size
QTY
Belantamab
GSK2857914
T771292061894-48-0
Belantamab (GSK2857914) is a humanized IgG1 monoclonal antibody against BCMA (TNFRSF17). Belantamab is a naked antibody to Belantamab mafodotin and can be used to synthesize antibody-active molecule conjugates (Belantamab mafodotin).
  • $263
In Stock
Size
QTY
Disitamab
T771592185868-98-6
Disitamab Vedotin (RC48-0) is a humanized monoclonal antibody that targets HER2 and can be utilized in creating antibody-drug conjugates (ADCs), specifically referred to as Disitamab Vedotin [1].
  • $289
In Stock
Size
QTY
Tisotumab
1E10, 1.00E+10
T773721418628-81-5
Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody targeting tissue factor (TF), utilized in antibody-conjugating drugs for cancer research.
  • $297
In Stock
Size
QTY
Enfortumab
T774051448664-46-7
Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.
  • $289
In Stock
Size
QTY
lorvotuzumab
T77406339306-30-8
Lorvotuzumab (Anti-NCAM1 CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.
  • $313
In Stock
Size
QTY
Lupartumab
BAY 1112623
T774121640971-88-5
Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A) and is employed in the synthesis of antibody-active molecular couplers for studying LYPD3-associated tumor diseases.
  • $297
In Stock
Size
QTY
Glembatumumab
T774391020264-78-1
Glembatumumab is a fully human IgG2 monoclonal antibody targeting the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. It is a naked antibody to Glembatumumab vedotin and can be used to study antibody-activated molecule couplings (Glembatumumab vedotin).
  • $263
In Stock
Size
QTY
Tamrintamab
SC-Mab003, SC34.28ss1, SC-003 mAb
T774632148325-59-9
Tamrintamab (SC-003 mAb) is an antibody targeting dipeptidase 3 (DPEP3), a potential cytotoxic agent for ovarian cancer research.
  • $1,690
In Stock
Size
QTY
Polatuzumab
T774772279068-37-8
Polatuzumab is a monoclonal antibody that targets CD79b and carries chemotherapeutically active molecules.Polatuzumab adheres to CD79b proteins and transports the chemotherapeutically active molecules into cells to kill them.Polatuzumab can be used to synthesize the antibody-compound coupling, Polatuzumab Vedotin.
  • $195
In Stock
Size
QTY
Upifitamab
T777492254118-43-7
Upifitamab is a naked antibody to upifitamab rilsodotin, which can be used to synthesize the antibody-coupled active molecule UPRI, which can be used to study cancer.
  • $347
In Stock
Size
QTY
Ozuriftamab
T778452460399-44-2
Ozuriftamab, a naked (human IgG1 kappa) antibody targeting the (receptor tyrosine kinase-like orphan receptor 2 (ROR2)), serves as a precursor for the synthesis of antibody-drug conjugates (ADCs) [1].
  • $186
2-4 weeks
Size
QTY
Vobramitamab
AEX-4089
T779052490556-50-6
Vobramitamab, a humanized B7-H3 monoclonal antibody (mAb), is conjugated to the prodrug seco-DUBA through a cleavable linker, creating the antibody-drug conjugate (ADC) known as MGC018 [1].
  • $332
2-4 weeks
Size
QTY
Briobacept
BR 3FC
T77906869881-54-9
Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2].
  • Inquiry Price
Size
QTY
Cantuzumab
T779111204740-23-7
Cantuzumab is a monoclonal antibody targeting the CanAg antigen with anti-tumor activity, used in the synthesis of the ADC compound cantuzumab mertansine.
  • $289
In Stock
Size
QTY
Mecbotamab
T806092460400-28-4
Mecbotamab vedotin (BA3011) is a humanized IgG1-κ antibody engineered to target the AXL receptor tyrosine kinase (AXL). Serving as a conditionally active biologic (CAB), mecbotamab is conjugated to monomethyl auristatin E (MMAE) through a cleavable linker, creating an antibody-drug conjugate (ADC) for therapeutic use [1] [2].
  • Inquiry Price
Size
QTY
Naratuximab
Anti-TSPAN26 CD37 Reference Antibody
T817031622327-39-2
Naratuximab (Anti-TSPAN26 CD37 Reference Antibody) is a humanized monoclonal antibody against CD37 that can be used to synthesize the ADC compound Naratuximab emtansine.
  • $189
In Stock
Size
QTY